



Morgan Lewis

INTELLECTUAL PROPERTY CONSIDERATIONS

Intellectual Property Goals



Drug development contracting will be easier if the Foundation controls the intellectual property relating to the drug candidate



Fundraising for clinical development may be facilitated if the program has commercial prospects (and supported by patents)

Generating Intellectual Property



Types of intellectual property:

Patents

Know-how: Results of studies, tools and materials (e.g., cell lines, reagents developed)



Potentially patentable subject matter:

Novel drug structures for treatment of disease

- Gene therapy construct
- Antisense Oligonucleotide / siRNA
- Gene editing constructs (gRNA)

Intellectual Property Generation: Sponsored Research



U.S. academic institutions will have intellectual property policies that require the University to own IP generated using the institution's resources (including with government grants)



Institutions outside the U.S. may be more flexible regarding IP ownership



Incorporate IP terms into the SRA to provide desired IP rights

Sponsored Research Agreements: Intellectual Property Terms



Non-exclusive right to use the results and research tools for Research and Development (with right to sublicense)



Option to negotiate an exclusive IP license for commercial purposes



Inventions and patent filings should be reported to Sponsor (may require Sponsor to pay for any patent filings)



If there is a basis for inventorship by the Foundation, co-ownership of intellectual property could result

Freedom-to-Operate



Freedom-to-operate (FTO) refers to the resolution of any third-party intellectual property rights (i.e., all required third party rights are licensed, acquired, or expired)



Timing for FTO is usually commercial drug launch (clinical activity is protected by safe-harbor)



QUESTIONS/COMMENTS?


Morgan Lewis

Our Global Reach

Africa
Asia Pacific
Europe
Latin America
Middle East
North America

Our Locations

Abu Dhabi
Almaty
Beijing*
Boston
Brussels
Century City
Chicago
Dallas
Dubai
Frankfurt
Hartford
Hong Kong*
Houston
London
Los Angeles
Miami
New York
Nur-Sultan
Orange County
Paris
Philadelphia
Pittsburgh
Princeton
San Francisco
Shanghai*
Silicon Valley
Singapore*
Tokyo
Washington, DC
Wilmington



Morgan Lewis

*Our Beijing and Shanghai offices operate as representative offices of Morgan, Lewis & Bockius LLP. In Hong Kong, Morgan Lewis operates through Morgan, Lewis & Bockius, which is a separate Hong Kong general partnership registered with The Law Society of Hong Kong as a registered foreign law firm operating in Association with Luk & Partners. Morgan Lewis Stamford LLC is a Singapore law corporation affiliated with Morgan, Lewis & Bockius LLP.

THANK YOU

© 2020 Morgan, Lewis & Bockius LLP
© 2020 Morgan Lewis Stamford LLC
© 2020 Morgan, Lewis & Bockius UK LLP

Morgan, Lewis & Bockius UK LLP is a limited liability partnership registered in England and Wales under number OC378797 and is a law firm authorised and regulated by the Solicitors Regulation Authority. The SRA authorisation number is 615176.

Our Beijing and Shanghai offices operate as representative offices of Morgan, Lewis & Bockius LLP. In Hong Kong, Morgan Lewis operates through Morgan, Lewis & Bockius, which is a separate Hong Kong general partnership registered with The Law Society of Hong Kong as a registered foreign law firm operating in Association with Luk & Partners. Morgan Lewis Stamford LLC is a Singapore law corporation affiliated with Morgan, Lewis & Bockius LLP.

This material is provided for your convenience and does not constitute legal advice or create an attorney-client relationship. Prior results do not guarantee similar outcomes. Attorney Advertising.